Table 2.
Study characteristics of the nine trials in the meta-analysis.
| Country, author, year | Study design | Treatment | S.S | Age (y) (Mean ± SD) | Baseline CFT (μm) | Baseline BCVA, logMAR | Cytokine recorded in our meta-analysis | Follow-up month |
|---|---|---|---|---|---|---|---|---|
| Japan, Takuya et al., 2021 | Self-control (prospective) | Ranibizumab | 25 | 62.9 ± 9.6 | 560 ± 166 | 0.51 ± 0.30 | VEGF, IL-6, IL-8, IP-10, and MCP-1 | 1 |
| Austria, Dominika et al., 2020 | Self-control (prospective) | Ranibizumab and dexamethasone | 9 | 66.9 ± 8.8; 64.6 ± 9.0∗ | 440 ± 144; 471.3 ± 122.6∗ | 0.70; 0.35∗ | VEGF, IL-6, IL-8, and MCP-1 | 2 |
| Canada, Verena et al., 2020 | Self-control (prospective) | Aflibercept | 17 | 57.2 ± 8.1 | 430.9 ± 85.5 | 0.39 ± 0.16 | VEGF, IL-6, IL-8, IP-10, and MCP-1 | 1 and 2 |
| Canada, Tina et al., 2019 | Self-control (prospective) | Ranibizumab | 35 | 62.4 ± 7.3 | 480.4 ± 117.4 | 0.60 ± 0.30 | VEGF, IL-6, IL-8, and MCP-1 | 2 |
| Italy, Mastropasqua et al., 2018 | Self-control (prospective) | Aflibercept | 20 | 63.4 ± 7.3 | 469.43 ± 181.91 | 0.46 ± 0.24 | VEGF, IL-6, IL-8, IP-10, and MCP-1 | 2 |
| Australia, Shueh et al., 2018 | Self-control (prospective) | Ranibizumab | 25 | 63.8 ± 9.6 | 484.5 ± 134.3 | 0.48 ± 0.20 | IL-6, IL-8, IP-10, MCP-1 | 2 |
| Canada, Roxane et al., 2018 | Self-control (prospective) | Ranibizumab | 48 | 61.9 ± 7.1 | 495.0 ± 134.6 | 0.60 ± 0.30 | VEGF, IL-6, IL-8, and MCP-1 | 2 |
| Japan, Tomoyasu et al., 2017 | Self-control (prospective) | Ranibizumab | 13 | 62.5 ± 11.9 | 570.0 ± 109.8 | 0.47 ± 0.25 | IL-6, IL-8, IP-10, and MCP-1 | 1 |
| Korea, Hee Jin Sohn et al., 2011 | Self-control (prospective) | Bevacizumab | 11 | 54.4 ± 10.2 | 387.7 ± 111.3 | 0.44 ± 0.32 | VEGF, IL-6, IL-8, IP-10, and MCP-1 | 1 |
Note. S.S, sample size; ∗the BCVA of two groups in the original text was 74.78 ± 14.85 and 67.22 ± 10.52 presented by Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores. The SD was not available due to lack of raw data.